Evotec Completes Acquisition of Renovis

Hamburg, Germany and South San Francisco, CA - May 2, 2008 - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that the merger has been successfully completed and that Renovis, Inc. (traded formerly on NASDAQ: RNVS) is now a wholly owned subsidiary of Evotec.
 
In exchange for each outstanding share of Renovis common stock, Renovis stockholders receive 0.5271 American Depositary Shares, or ADSs, of Evotec, which have been approved for listing on the NASDAQ Global Market under the trading symbol "EVTC". The first day of trading is expected to be on or about May 5, 2008 and the ADSs will trade on a "when issued" basis under the symbol "EVTCV" until they are eligible for normal trade settlement, currently anticipated to be within two weeks of the acquisition.
 
Each Evotec ADS represents two ordinary shares of Evotec. As a result, Evotec is issuing an aggregate of 34,970,268 new ordinary shares, which underly the ADSs issued to Renovis stockholders. Current Evotec stockholders now own approximately 68.8% of the combined company and Renovis stockholders own up to 31.2%. To ensure that new Evotec shareholders will be able to participate in this year's Annual General Meeting, Evotec has scheduled the meeting to be held on August 28, 2008.
 
Lehman Brothers Inc. served as the financial advisor to Evotec.  Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Freshfields Bruckhaus Deringer served as Evotec's legal counsel.
 
Contact: Anne Hennecke, Senior Vice President, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com